drugset
drugset / Trial / NCT03850730

Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia

NCT03850730 ↗

Phase 1/2 Unknown 30 enrolled Cure HHT University of North Carolina · collab
NaSingle-groupOpen-labelTreatment

Summary

Investigators will test the value of very low dose Pazopanib administered to patients with hereditary hemorrhagic telangiectasia for the reduction in the severity of nose bleeds in those with frequent and long duration bleeding episodes.

Timeline

Start
2023-07-01
Primary completion
2025-06-30
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Pazopanib Small molecule 25 mg Oral
Subject Pazopanib Small molecule 50 mg Oral

Indications

hereditary hemorrhagic telangiectasia